DSGN · Design Therapeutics Inc
United States · RS rating 35 · As of 2026-11-03
| Price | 10.34 USD |
|---|---|
| 1-day change | +1.9% |
| RS rating (overall / 1M / 3M / 12M) | 35 / 25 / 27 / 86 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 26 / 29 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +10.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +35.1% |
| Market cap (USD) | $788.2M |